Robert Lindsay Sutherland

Title: Innovations and Contributions of Robert Lindsay Sutherland

Introduction

Robert Lindsay Sutherland is a notable inventor based in Lindfield, Australia. He has made significant contributions to the field of medical research, particularly in the area of cancer genetics. With a total of two patents to his name, Sutherland's work has the potential to impact the diagnosis and treatment of hyperproliferative diseases.

Latest Patents

Sutherland's latest patents include a novel human tumor suppressor gene, designated EDD. This gene encodes a product that exhibits significant amino acid sequence identity with the HYD protein from hyperplastic discs and the 100 kDa HECT domain protein from rats. The EDD gene appears to represent a tumor suppressor gene, and detecting a polymorphism or alteration in this gene may be useful for diagnosing or determining a predisposition to diseases such as cancer. Additionally, he has developed GDU, a novel signaling protein, which provides the nucleotide and amino acid sequence of a previously unidentified erbB receptor target.

Career Highlights

Sutherland is affiliated with the Garvan Institute of Medical Research, where he conducts his research. His work focuses on understanding the genetic factors that contribute to cancer and other diseases. His innovative approaches have garnered attention in the scientific community.

Collaborations

Sutherland has collaborated with notable colleagues, including Roger John Daly and Michelle J Callaghan. These collaborations have furthered research efforts and contributed to advancements in their respective fields.

Conclusion

Robert Lindsay Sutherland's contributions to medical research and his innovative patents highlight his commitment to advancing our understanding of cancer genetics. His work continues to pave the way for future discoveries in the field.